Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
Prostate carcinoma (PC) is the second most common cancer in men. When the disease becomes unresponsive to androgen deprivation therapy, the remaining treatment options are of limited benefit. Despite intense efforts, none of the T cell-based immunotherapeutic strategies that meanwhile have become a...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/3/549 |
id |
doaj-1f0ba4db636e4e4da4b0cbd26021a580 |
---|---|
record_format |
Article |
spelling |
doaj-1f0ba4db636e4e4da4b0cbd26021a5802021-02-02T00:05:05ZengMDPI AGCancers2072-66942021-02-011354954910.3390/cancers13030549Bispecific Antibodies in Prostate Cancer Therapy: Current Status and PerspectivesJonas S. Heitmann0Martin Pfluegler1Gundram Jung2Helmut R. Salih3Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, GermanyClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, GermanyDFG Cluster of Excellence 2180 “Image-Guided and Functional Instructed Tumor Therapy” (IFIT), University of Tübingen, 72076 Tübingen, GermanyClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, GermanyProstate carcinoma (PC) is the second most common cancer in men. When the disease becomes unresponsive to androgen deprivation therapy, the remaining treatment options are of limited benefit. Despite intense efforts, none of the T cell-based immunotherapeutic strategies that meanwhile have become a cornerstone for treatment of other malignancies is established in PC. This refers to immune checkpoint inhibition (CI), which generally reinforces T cell immunity as well as chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) that stimulate the T cell receptor/CD3-complex and mobilize T cells in a targeted manner. In general, compared to CAR-T cells, bsAb would have the advantage of being an “off the shelf” reagent associated with less preparative effort, but at present, despite enormous efforts, neither CAR-T cells nor bsAbs are successful in solid tumors. Here, we focus on the various bispecific constructs that are presently in development for treatment of PC, and discuss underlying concepts and the state of clinical evaluation as well as future perspectives.https://www.mdpi.com/2072-6694/13/3/549bispecific antibodyprostate cancerCRPC |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jonas S. Heitmann Martin Pfluegler Gundram Jung Helmut R. Salih |
spellingShingle |
Jonas S. Heitmann Martin Pfluegler Gundram Jung Helmut R. Salih Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives Cancers bispecific antibody prostate cancer CRPC |
author_facet |
Jonas S. Heitmann Martin Pfluegler Gundram Jung Helmut R. Salih |
author_sort |
Jonas S. Heitmann |
title |
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives |
title_short |
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives |
title_full |
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives |
title_fullStr |
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives |
title_full_unstemmed |
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives |
title_sort |
bispecific antibodies in prostate cancer therapy: current status and perspectives |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-02-01 |
description |
Prostate carcinoma (PC) is the second most common cancer in men. When the disease becomes unresponsive to androgen deprivation therapy, the remaining treatment options are of limited benefit. Despite intense efforts, none of the T cell-based immunotherapeutic strategies that meanwhile have become a cornerstone for treatment of other malignancies is established in PC. This refers to immune checkpoint inhibition (CI), which generally reinforces T cell immunity as well as chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) that stimulate the T cell receptor/CD3-complex and mobilize T cells in a targeted manner. In general, compared to CAR-T cells, bsAb would have the advantage of being an “off the shelf” reagent associated with less preparative effort, but at present, despite enormous efforts, neither CAR-T cells nor bsAbs are successful in solid tumors. Here, we focus on the various bispecific constructs that are presently in development for treatment of PC, and discuss underlying concepts and the state of clinical evaluation as well as future perspectives. |
topic |
bispecific antibody prostate cancer CRPC |
url |
https://www.mdpi.com/2072-6694/13/3/549 |
work_keys_str_mv |
AT jonassheitmann bispecificantibodiesinprostatecancertherapycurrentstatusandperspectives AT martinpfluegler bispecificantibodiesinprostatecancertherapycurrentstatusandperspectives AT gundramjung bispecificantibodiesinprostatecancertherapycurrentstatusandperspectives AT helmutrsalih bispecificantibodiesinprostatecancertherapycurrentstatusandperspectives |
_version_ |
1724314573680410624 |